Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia

Hillary Prescott, Hagop Kantarjian, Jorge Cortes, Farhad Ravandi

Research output: Contribution to journalReview article

Abstract

The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in acute leukemias. Mutations involving FLT3 are among the most common molecular abnormalities in acute myelogenous leukemia (AML). Available evidence suggests that these molecular lesions confer a shorter disease-free survival and overall survival in patients with intermediate-risk cytogenetics. Therefore, substantial interest in FLT3 as a therapeutic target has led to the development of several promising inhibitors that target this tyrosine kinase. Areas covered: This review covers the molecular pathways associated with FLT3 activation in patients with AML, the biological rationale for inhibiting FLT3 and recent clinical progress with FLT3 inhibitors for the treatment of AML. Six FLT3 inhibitors undergoing clinical evaluation are discussed. A review of selected published manuscripts on the subject of FLT3 inhibition in AML and a search of the English language manuscripts in PubMed using the index words FLT3 and AML were conducted and articles of interest selected. Expert opinion: Mutated forms of FLT3, specifically FLT3-internal tandem duplication, have a significant impact on the prognosis of AML patients, particularly those with a normal karyotype. Inhibiting FLT3 may lead to clinical benefit for patients with AML. Newly developed FLT3 inhibitors have shown encouraging activity as monotherapy and in combination with other therapeutic agents.

Original languageEnglish (US)
Pages (from-to)407-423
Number of pages17
JournalExpert Opinion on Emerging Drugs
Volume16
Issue number3
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Therapeutics
Manuscripts
Expert Testimony
Karyotype
PubMed
Cytogenetics
Disease-Free Survival
Leukemia
Language

Keywords

  • acute myelogenous leukemia
  • FLT3
  • FLT3 inhibitor
  • FLT3-ITD

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. / Prescott, Hillary; Kantarjian, Hagop; Cortes, Jorge; Ravandi, Farhad.

In: Expert Opinion on Emerging Drugs, Vol. 16, No. 3, 01.09.2011, p. 407-423.

Research output: Contribution to journalReview article

Prescott, Hillary ; Kantarjian, Hagop ; Cortes, Jorge ; Ravandi, Farhad. / Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. In: Expert Opinion on Emerging Drugs. 2011 ; Vol. 16, No. 3. pp. 407-423.
@article{e30985a8815f4ef89bf502a81893a7fc,
title = "Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia",
abstract = "The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in acute leukemias. Mutations involving FLT3 are among the most common molecular abnormalities in acute myelogenous leukemia (AML). Available evidence suggests that these molecular lesions confer a shorter disease-free survival and overall survival in patients with intermediate-risk cytogenetics. Therefore, substantial interest in FLT3 as a therapeutic target has led to the development of several promising inhibitors that target this tyrosine kinase. Areas covered: This review covers the molecular pathways associated with FLT3 activation in patients with AML, the biological rationale for inhibiting FLT3 and recent clinical progress with FLT3 inhibitors for the treatment of AML. Six FLT3 inhibitors undergoing clinical evaluation are discussed. A review of selected published manuscripts on the subject of FLT3 inhibition in AML and a search of the English language manuscripts in PubMed using the index words FLT3 and AML were conducted and articles of interest selected. Expert opinion: Mutated forms of FLT3, specifically FLT3-internal tandem duplication, have a significant impact on the prognosis of AML patients, particularly those with a normal karyotype. Inhibiting FLT3 may lead to clinical benefit for patients with AML. Newly developed FLT3 inhibitors have shown encouraging activity as monotherapy and in combination with other therapeutic agents.",
keywords = "acute myelogenous leukemia, FLT3, FLT3 inhibitor, FLT3-ITD",
author = "Hillary Prescott and Hagop Kantarjian and Jorge Cortes and Farhad Ravandi",
year = "2011",
month = "9",
day = "1",
doi = "10.1517/14728214.2011.568938",
language = "English (US)",
volume = "16",
pages = "407--423",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia

AU - Prescott, Hillary

AU - Kantarjian, Hagop

AU - Cortes, Jorge

AU - Ravandi, Farhad

PY - 2011/9/1

Y1 - 2011/9/1

N2 - The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in acute leukemias. Mutations involving FLT3 are among the most common molecular abnormalities in acute myelogenous leukemia (AML). Available evidence suggests that these molecular lesions confer a shorter disease-free survival and overall survival in patients with intermediate-risk cytogenetics. Therefore, substantial interest in FLT3 as a therapeutic target has led to the development of several promising inhibitors that target this tyrosine kinase. Areas covered: This review covers the molecular pathways associated with FLT3 activation in patients with AML, the biological rationale for inhibiting FLT3 and recent clinical progress with FLT3 inhibitors for the treatment of AML. Six FLT3 inhibitors undergoing clinical evaluation are discussed. A review of selected published manuscripts on the subject of FLT3 inhibition in AML and a search of the English language manuscripts in PubMed using the index words FLT3 and AML were conducted and articles of interest selected. Expert opinion: Mutated forms of FLT3, specifically FLT3-internal tandem duplication, have a significant impact on the prognosis of AML patients, particularly those with a normal karyotype. Inhibiting FLT3 may lead to clinical benefit for patients with AML. Newly developed FLT3 inhibitors have shown encouraging activity as monotherapy and in combination with other therapeutic agents.

AB - The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in acute leukemias. Mutations involving FLT3 are among the most common molecular abnormalities in acute myelogenous leukemia (AML). Available evidence suggests that these molecular lesions confer a shorter disease-free survival and overall survival in patients with intermediate-risk cytogenetics. Therefore, substantial interest in FLT3 as a therapeutic target has led to the development of several promising inhibitors that target this tyrosine kinase. Areas covered: This review covers the molecular pathways associated with FLT3 activation in patients with AML, the biological rationale for inhibiting FLT3 and recent clinical progress with FLT3 inhibitors for the treatment of AML. Six FLT3 inhibitors undergoing clinical evaluation are discussed. A review of selected published manuscripts on the subject of FLT3 inhibition in AML and a search of the English language manuscripts in PubMed using the index words FLT3 and AML were conducted and articles of interest selected. Expert opinion: Mutated forms of FLT3, specifically FLT3-internal tandem duplication, have a significant impact on the prognosis of AML patients, particularly those with a normal karyotype. Inhibiting FLT3 may lead to clinical benefit for patients with AML. Newly developed FLT3 inhibitors have shown encouraging activity as monotherapy and in combination with other therapeutic agents.

KW - acute myelogenous leukemia

KW - FLT3

KW - FLT3 inhibitor

KW - FLT3-ITD

UR - http://www.scopus.com/inward/record.url?scp=80052015797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052015797&partnerID=8YFLogxK

U2 - 10.1517/14728214.2011.568938

DO - 10.1517/14728214.2011.568938

M3 - Review article

C2 - 21417961

AN - SCOPUS:80052015797

VL - 16

SP - 407

EP - 423

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -